modelValaciclovir
Extends from Pharmacolibrary.Drugs.ATC.J.J05AB11.
Information
| name: | Valaciclovir | |
| ATC code: | J05AB11 | route: | oral |
| compartments: | 1 | |
| dosage: | 1000 | mg |
| volume of distribution: | 49.3 | L |
| clearance: | 28.7 | L/h |
| other parameters in model implementation | ||
Valaciclovir is an antiviral prodrug that is rapidly converted in vivo to acyclovir, an agent used primarily for the treatment of herpes simplex virus (HSV) infections and varicella-zoster virus (VZV) infections. It is approved and commonly used today for herpes simplex (genital herpes, cold sores), herpes zoster (shingles), and, sometimes, for cytomegalovirus prophylaxis in transplant patients.
Pharmacokinetics
Pharmacokinetic parameters in healthy adult volunteers after a single oral dose of valaciclovir 1000 mg, values reported for acyclovir (active metabolite).
References
Zeng, L, et al., & McLachlan, AJ (2009). Population pharmacokinetics of acyclovir in children and young people with malignancy after administration of intravenous acyclovir or oral valacyclovir. Antimicrobial agents and chemotherapy 53(7) 2918–2927. DOI:10.1128/AAC.01138-08 PUBMED:https://pubmed.ncbi.nlm.nih.gov/19414579
Patel, R (1997). Valaciclovir: development, clinical utility and potential. Expert opinion on investigational drugs 6(2) 173–189. DOI:10.1517/13543784.6.2.173 PUBMED:https://pubmed.ncbi.nlm.nih.gov/15989601
Faure-Bardon, V, et al., & Ville, Y (2025). Quantification of maternal and fetal valaciclovir exposure in a pharmacokinetic study of cytomegalovirus-infected pregnant women treated to prevent vertical transmission. The Journal of antimicrobial chemotherapy 80(3) 760–766. DOI:10.1093/jac/dkae470 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39810739
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)